255 related articles for article (PubMed ID: 32582721)
21. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
Hohnloser SH; Camm AJ; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Lanz HJ; Rauer H; Reimitz PE; Smolnik R; Kautzner J
Europace; 2021 Jan; 23(1):65-72. PubMed ID: 33249467
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
23. Uninterrupted use of direct oral anticoagulants versus vitamin K antagonists for catheter ablation of atrial fibrillation with PVAC gold: incidence of silent cerebral microembolic events.
Wieczorek M; Bogossian H; Bandorski D; Hoeltgen R
J Interv Card Electrophysiol; 2021 Oct; 62(1):39-47. PubMed ID: 32951115
[TBL] [Abstract][Full Text] [Related]
24. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence.
Martin AC; Godier A; Narayanan K; Smadja DM; Marijon E
Circulation; 2018 Aug; 138(6):627-633. PubMed ID: 30354610
[TBL] [Abstract][Full Text] [Related]
25. Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials.
Yang Q; Chen X; Zhai J; Dang Y
Acta Cardiol; 2022 May; 77(3):257-263. PubMed ID: 33871328
[TBL] [Abstract][Full Text] [Related]
26. Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation.
Müller P; Halbfass P; Szöllösi A; Dietrich JW; Fochler F; Nentwich K; Roos M; Krug J; Schmitt R; Mügge A; Deneke T
J Interv Card Electrophysiol; 2016 Sep; 46(3):203-11. PubMed ID: 27020439
[TBL] [Abstract][Full Text] [Related]
27. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
[TBL] [Abstract][Full Text] [Related]
28. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
[TBL] [Abstract][Full Text] [Related]
29. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
[TBL] [Abstract][Full Text] [Related]
30. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
[TBL] [Abstract][Full Text] [Related]
31. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation.
Russo V; Bottino R; Rago A; Papa AA; Liccardo B; D'Onofrio A; Golino P; Nigro G
Semin Thromb Hemost; 2020 Nov; 46(8):970-976. PubMed ID: 33105504
[TBL] [Abstract][Full Text] [Related]
32. Use of NOACs Versus Vitamin K Antagonist in Atrial Fibrillation Catheter Ablation: An Updated Meta-analysis With Subgroup Analysis.
Bhogal S; Mawa K; Bhandari T; Ramu V
Am J Ther; 2021 Aug; 29(1):e56-e63. PubMed ID: 34469922
[TBL] [Abstract][Full Text] [Related]
33. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Calkins H; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Serota H; Nordaby M; Guiver K; Biss B; Brouwer MA; Grimaldi M;
N Engl J Med; 2017 Apr; 376(17):1627-1636. PubMed ID: 28317415
[TBL] [Abstract][Full Text] [Related]
34. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Hohnloser SH; Basic E; Nabauer M
Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
[TBL] [Abstract][Full Text] [Related]
35. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
[TBL] [Abstract][Full Text] [Related]
36. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin.
Zhao Y; Yang Y; Tang X; Yu X; Zhang L; Xiao H
J Interv Card Electrophysiol; 2017 Apr; 48(3):267-282. PubMed ID: 28078536
[TBL] [Abstract][Full Text] [Related]
37. Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
Hansen PS; Sanchez R; Walfridsson H
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836793
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
Ukaigwe A; Shrestha P; Karmacharya P; Hussain SK; Samii S; Gonzalez MD; Wolbrette D; Naccarrelli GV
J Interv Card Electrophysiol; 2017 Mar; 48(2):223-233. PubMed ID: 27771820
[TBL] [Abstract][Full Text] [Related]
39. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of safety and efficacy of oral anticoagulants in patients requiring catheter ablation for atrial fibrillation.
Rahman H; Khan SU; DePersis M; Hammad T; Nasir F; Kaluski E
Cardiovasc Revasc Med; 2019 Feb; 20(2):147-152. PubMed ID: 29786530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
